A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Public ClinicalTrials.gov record NCT07783425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking participants who: * Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48. Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.
Study identification
- NCT ID
- NCT07783425
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,375 participants
Conditions and interventions
Conditions
Interventions
- Tilrekimig Drug
- Dupilumab Drug
- Placebo for Tilrekimig Other
- Placebo for Dupilumab Other
Drug · Other
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2026 (Actual)
- Primary completion
- Sep 8, 2028 (Estimated)
- Completion
- Jun 15, 2029 (Estimated)
- Last update posted
- Oct 6, 2026
2026 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance Dermatology & MOHS Center | Phoenix | Arizona | 85032 | Not yet recruiting |
| Marvel Clinical Research | Huntington Beach | California | 92647 | Recruiting |
| Northridge Clinical Trials, LLC | Northridge | California | 91325 | Recruiting |
| Marietta Dermatology Clinical Research, Inc. | Marietta | Georgia | 30060 | Recruiting |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | Recruiting |
| Revival Research Institute, LLC | Troy | Michigan | 48084 | Not yet recruiting |
| Respiratory Medicine Research Institute of Michigan, PLC | Ypsilanti | Michigan | 48197 | Not yet recruiting |
| Vital Prospects Clinical Research Institute., PC | Tulsa | Oklahoma | 74136 | Recruiting |
| Best Skin Research, LLC | Camp Hill | Pennsylvania | 17011 | Not yet recruiting |
| Clinical Neuroscience Solutions, LLC. | Memphis | Tennessee | 38119 | Recruiting |
| Dermatology Treatment and Research Center | Dallas | Texas | 75230 | Not yet recruiting |
| Complete Dermatology | Sugar Land | Texas | 77479 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07783425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07783425 live on ClinicalTrials.gov.